⏳ Fetching live dividend data...
Home › Calculator › GTHX Dividend Calculator 2026
G1 Therapeutics, Inc. · NASDAQ
Price: $7.16 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in GTHX → $117.4K in 10 years · $2,136.87/month
G1 Therapeutics, Inc. operates as a clinical-stage biopharmaceutical enterprise focused on identifying, advancing, and ultimately commercializing small-molecule therapeutics to address various cancers. Their flagship commercial offering, COSELA, is designed to reduce chemotherapy-induced bone marrow suppression in adult patients with extensive-stage small cell lung cancer, administered prior to specific platinum/etoposide- or topotecan-containing regimens. The company is also actively progressing several investigational compounds. Trilaciclib, a CDK4/6 inhibitor, is currently undergoing extensive clinical evaluation, including Phase III studies for first-line colorectal cancer and first-line triple-negative breast cancer. Additionally, it is in Phase II trials for initial bladder cancer treatment, in combination with an antibody-drug conjugate, and as a neoadjuvant therapy for breast cancer. Their development pipeline further includes lerociclib, an oral CDK4/6 inhibitor intended for multiple oncological applications, and rintodestrant, an orally administered selective estrogen receptor degrader, which is in Phase IIa clinical trials for estrogen receptor-positive, HER2-negative breast cancer. G1 Therapeutics has forged several strategic licensing agreements. They have partnered with EQRx, Inc. and Genor Biopharma Co. Inc. for the oral formulation of lerociclib, encompassing all human indications. A separate collaboration with Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. covers the parenteral development and market introduction of trilaciclib for any human indication. Furthermore, the company works with ARC Therapeutics on a CDK2 inhibitor, designated for both human and veterinary uses. Established in 2008, G1 Therapeutics, Inc. is headquartered in Research Triangle Park, North Carolina.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open GTHX position with:
Real after-tax yield depends on where you live and how you hold GTHX.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 27.93% | 25.13% | $2,793 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 23.74% | 20.94% | $2,374 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 22.34% | 19.54% | $2,234 / yr |
| 🇬🇧 UK ISA | 0% | 27.93% | 25.13% | $2,793 / yr |
| 🇬🇧 UK Taxable | 8.75% | 25.49% | 22.69% | $2,549 / yr |
| 🇨🇦 TFSA | 0% | 27.93% | 25.13% | $2,793 / yr |
| 🇨🇦 CA Taxable | 25% | 20.95% | 18.15% | $2,095 / yr |
| 🇦🇺 Super (pension) | 15% | 23.74% | 20.94% | $2,374 / yr |
| 🇦🇺 AU Taxable | 30% | 19.55% | 16.75% | $1,955 / yr |
| 🇩🇪 DE Taxable | 26.375% | 20.56% | 17.76% | $2,056 / yr |
| 🇫🇷 FR Taxable | 30% | 19.55% | 16.75% | $1,955 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
GTHX pays quarterly — 4 times per year. Next ex-div: TBD.
How GTHX compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for GTHX sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| D-Return | 2024-09-18 | 20,000 | $7.15 | $143.0K | ||
| D-Return | 2024-09-18 | 30,000 | $2.99 | $89.7K | ||
| U-Tender | 2024-09-18 | 10,000 | — | — | ||
| D-Return | 2024-09-18 | 30,000 | $2.83 | $84.9K | ||
| D-Return | 2024-09-18 | 30,000 | $5.30 | $159.0K | ||
| D-Return | 2024-09-18 | 138,151 | $7.15 | $987.8K | ||
| U-Tender | 2024-09-18 | 6,674 | — | — | ||
| D-Return | 2024-09-18 | 55,875 | $2.97 | $165.9K | ||
| D-Return | 2024-09-18 | 150,000 | $2.88 | $432.0K | ||
| D-Return | 2024-09-18 | 20,000 | $7.15 | $143.0K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the GTHX dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
G1 Therapeutics, Inc. (GTHX) is currently trading at $7.16, 74% below its 52-week high. The current dividend yield is 27.93% based on an annual payout of $2.00 per share.
G1 Therapeutics, Inc. (GTHX) is a healthcare stock currently trading at $7.16 with a dividend yield of 27.93%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →